Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) EBT Margin (2023 - 2025)

Historic EBT Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 967.66%.

  • Tonix Pharmaceuticals Holding's EBT Margin fell 4064600.0% to 967.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 948.86%, marking a year-over-year increase of 3072300.0%. This contributed to the annual value of 1354.28% for FY2024, which is 900700.0% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's EBT Margin stood at 967.66%, which was down 4064600.0% from 1369.02% recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's EBT Margin ranged from a high of 561.2% in Q3 2024 and a low of 3501.59% during Q2 2024
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median EBT Margin value was 860.23% (recorded in 2024), while the average stood at 1135.06%.
  • Data for Tonix Pharmaceuticals Holding's EBT Margin shows a peak YoY increase of 21325700bps (in 2025) and a maximum YoY decrease of -4064600bps (in 2025) over the last 5 years.
  • Tonix Pharmaceuticals Holding's EBT Margin (Quarter) stood at 723.0% in 2023, then fell by -20bps to 870.64% in 2024, then fell by -11bps to 967.66% in 2025.
  • Its last three reported values are 967.66% in Q3 2025, 1369.02% for Q2 2025, and 660.93% during Q1 2025.